Asthma and COVID-19: What do we know now

The COVID-19 pandemic has presented challenges in symptomology identification, diagnosis, management and follow-up in common respiratory diseases, and in particular asthma. Research is rapidly ongoing to try and understand how the SARS-CoV-2 virus affects individuals with asthma, as well as, how und...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes-Visentin, Alexzandra, Paul, Anthea B Mahesan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588760/
https://www.ncbi.nlm.nih.gov/pubmed/33173369
http://dx.doi.org/10.1177/1179548420966242
_version_ 1783600431162720256
author Hughes-Visentin, Alexzandra
Paul, Anthea B Mahesan
author_facet Hughes-Visentin, Alexzandra
Paul, Anthea B Mahesan
author_sort Hughes-Visentin, Alexzandra
collection PubMed
description The COVID-19 pandemic has presented challenges in symptomology identification, diagnosis, management and follow-up in common respiratory diseases, and in particular asthma. Research is rapidly ongoing to try and understand how the SARS-CoV-2 virus affects individuals with asthma, as well as, how underlying asthma affects Covid-19 risk, symptomology and prognosis. In light of this unique medical challenge, clinicians are faced with case-by-case based decisions to implement or continue current asthma therapy. This review will discuss the current literature regarding asthma and COVID-19 based on best available evidence at this time (See box 1).
format Online
Article
Text
id pubmed-7588760
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-75887602020-11-09 Asthma and COVID-19: What do we know now Hughes-Visentin, Alexzandra Paul, Anthea B Mahesan Clin Med Insights Circ Respir Pulm Med Review The COVID-19 pandemic has presented challenges in symptomology identification, diagnosis, management and follow-up in common respiratory diseases, and in particular asthma. Research is rapidly ongoing to try and understand how the SARS-CoV-2 virus affects individuals with asthma, as well as, how underlying asthma affects Covid-19 risk, symptomology and prognosis. In light of this unique medical challenge, clinicians are faced with case-by-case based decisions to implement or continue current asthma therapy. This review will discuss the current literature regarding asthma and COVID-19 based on best available evidence at this time (See box 1). SAGE Publications 2020-10-23 /pmc/articles/PMC7588760/ /pubmed/33173369 http://dx.doi.org/10.1177/1179548420966242 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Hughes-Visentin, Alexzandra
Paul, Anthea B Mahesan
Asthma and COVID-19: What do we know now
title Asthma and COVID-19: What do we know now
title_full Asthma and COVID-19: What do we know now
title_fullStr Asthma and COVID-19: What do we know now
title_full_unstemmed Asthma and COVID-19: What do we know now
title_short Asthma and COVID-19: What do we know now
title_sort asthma and covid-19: what do we know now
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588760/
https://www.ncbi.nlm.nih.gov/pubmed/33173369
http://dx.doi.org/10.1177/1179548420966242
work_keys_str_mv AT hughesvisentinalexzandra asthmaandcovid19whatdoweknownow
AT paulantheabmahesan asthmaandcovid19whatdoweknownow

Ejemplares similares